Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dendritic cell + trans-arterial embolization followed by radiofrequency ablation for hepatocellular carcinoma
jRCTc050200107Not yet recruiting
- Start
- Jan 2021
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of TriMix-DC in hepatocellular carcinoma (HCC). Primary endpoint: Efficacy. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
TriMix-DC
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCTc050200107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTc050200107.